TY - JOUR
T1 - Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease
AU - Fan, Chengming
AU - Joshi, Jyotsna
AU - Li, Fan
AU - Xu, Bing
AU - Khan, Mahmood
AU - Yang, Jinfu
AU - Zhu, Wuqiang
N1 - Funding Information:
The authors would like to thank Drs. Jianyi Zhang and Gangjian Qin in The University of Alabama at Birmingham for their continued support. Funding. This work was supported by the National Institutes of Health (National Heart, Lung, and Blood Institute R01 grant HL142627 to WZ and R01HL136232 to MK), and the American Heart Association Scientist Development Grant (16SDG30410018 to WZ). CF was supported by the Fundamental Research Funds from the Central South University (2017zzts234).
Publisher Copyright:
© Copyright © 2020 Fan, Joshi, Li, Xu, Khan, Yang and Zhu.
PY - 2020/6/24
Y1 - 2020/6/24
N2 - The regenerative capacity of an adult cardiac tissue is insufficient to repair the massive loss of heart tissue, particularly cardiomyocytes (CMs), following ischemia or other catastrophic myocardial injuries. The delivery methods of therapeutics agents, such as small molecules, growth factors, exosomes, cells, and engineered tissues have significantly advanced in medical science. Furthermore, with the controlled release characteristics, nanoparticle (NP) systems carrying drugs are promising in enhancing the cardioprotective potential of drugs in patients with cardiac ischemic events. NPs can provide sustained exposure precisely to the infarcted heart via direct intramyocardial injection or intravenous injection with active targets. In this review, we present the recent advances and challenges of different types of NPs loaded with agents for the repair of myocardial infarcted heart tissue.
AB - The regenerative capacity of an adult cardiac tissue is insufficient to repair the massive loss of heart tissue, particularly cardiomyocytes (CMs), following ischemia or other catastrophic myocardial injuries. The delivery methods of therapeutics agents, such as small molecules, growth factors, exosomes, cells, and engineered tissues have significantly advanced in medical science. Furthermore, with the controlled release characteristics, nanoparticle (NP) systems carrying drugs are promising in enhancing the cardioprotective potential of drugs in patients with cardiac ischemic events. NPs can provide sustained exposure precisely to the infarcted heart via direct intramyocardial injection or intravenous injection with active targets. In this review, we present the recent advances and challenges of different types of NPs loaded with agents for the repair of myocardial infarcted heart tissue.
KW - cardiac repair
KW - controlled release
KW - drug delivery systems
KW - myocardial infarction
KW - nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85087734164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087734164&partnerID=8YFLogxK
U2 - 10.3389/fbioe.2020.00687
DO - 10.3389/fbioe.2020.00687
M3 - Review article
AN - SCOPUS:85087734164
SN - 2296-4185
VL - 8
JO - Frontiers in Bioengineering and Biotechnology
JF - Frontiers in Bioengineering and Biotechnology
M1 - 687
ER -